(Q34861980)

4 August 2017

1 reference

title

Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management (English)

1 reference

4 August 2017

0 references

Smets F

1

1 reference

4 August 2017

Sokal EM

series ordinal

2

1 reference

4 August 2017

language of work or name

1 reference

1 August 2002

1 reference

Pediatric Transplantation

4 August 2017

published in

1 reference

4 August 2017

volume

6

1 reference

4 August 2017

issue

4

1 reference

4 August 2017

page(s)

280-287

1 reference

Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: A growing concern

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Characteristics of Epstein-Barr virus primary infection in pediatric liver transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Lymphoproliferative disorders after organ transplantation in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Rational management of posttransplant lymphoproliferative disorder in pediatric recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Long-term T-cell-mediated immunity to Epstein-Barr virus in renal-allograft recipients receiving cyclosporin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

The biology of Epstein-Barr virus: lessons learned from the virus and the host

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Epstein-Barr virus latent infection in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Major histocompatibility complex class I-restricted cytotoxic T lymphocyte responses to Epstein-Barr virus in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

CD8(+) T-cell selection, function, and death in the primary immune response in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Predictive value of Epstein-Barr virus genome copy number and BZLF1 expression in blood lymphocytes of transplant recipients at risk for lymphoproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Long-term T-cell-mediated immunity to epstein-barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Studies on long-term T-cell-mediated immunity to epstein-barr virus in immunosuppressed renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Non-correlation of in vivo and in vitro parameters of Epstein-Barr virus persistence suggests heterogeneity of B cell infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Analysis of the T-cell micro-environment in Epstein-Barr virus-related post-transplantation B lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Interferon gamma (IFN-gamma) deficiency in generalized Epstein-Barr virus infection with interstitial lymphoid and granulomatous pneumonia, focal cerebral lesions, and genital ulcers: remission following IFN-gamma substitution therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Immunoregulation during acute infection with Epstein-Barr virus: dynamics of interferon and 2',5'-oligoadenylate synthetase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Longitudinal dynamics of Epstein-Barr virus-specific cytotoxic T lymphocytes during posttransplant lymphoproliferative disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Prospective longitudinal analysis of quantitative Epstein-Barr virus polymerase chain reaction in pediatric liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Effects of immunotherapy on experimental immunodeficiency-related lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Acute Tonsillitis as the First Manifestation of Post-Transplant Lymphoproliferative Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Post-transplant lymphoproliferative disease in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Lymphoproliferative disease after pediatric liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Clonal Expansions in Acute EBV Infection Are Detectable in the CD8 and not the CD4 Subset and Persist with a Variable CD45 Phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Posttransplantation lymphoproliferative disorder: endoscopic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.02029.X

10.1034/J.1399-3046.2002.02029.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference